Skip to main content
padlock icon - secure page this page is secure

Computer-Aided Molecular Modeling: A Predictive Approach in the Design of Nanoparticulate Drug Delivery System

Buy Article:

$106.67 + tax (Refund Policy)

The purpose of the present work was to investigate Computer-Aided Molecular Modeling (CAMM) as a predictive approach in the design of polymeric nanoparticulate drug delivery systems. Three-model drugs doxorubicin (water soluble), silymarin (sparingly water soluble) and gliclazide (water insoluble) and six polymers with varied functional groups namely, alginic acid, sodium alginate, chitosan, methyl-vinyl–ether-co-malic acid (Gantrez AN119) and the acrylic polymers (Eudragit L100 and Eudragit RSPO) were selected for the CAMM study. Drug loaded polymeric nanoparticles were prepared at a drug:polymer ratio of 1:2 and experimental encapsulation efficiency values were determined. The structures of the drugs and polymers were built individually and their minimum energy conformations determined first using Molecular mechanics force field followed by AM1 Semi-Empirical Quantum mechanics and finally by ab initio method with minimal basis set. Various structural descriptors were evaluated. Cluster analysis, Non linear regression, and Artificial Neural Network (ANN) models were used to predict encapsulation efficiency (EE). CAMM study suggested that EE directly correlated with interaction energy of the drug and polymer and inversely with the hydration energy of the drug. Conclusive results were not obtained using cluster analysis. Hence, various a non-linear regression models were derived to predict the EE. Finally, the following model was derived to predict encapsulation efficiency: EE = −153.1 + 16.99 * IntEn−0.97 * HydEn−0.32 * IntEn2, where R2, R2adj R2pre, and F ratio were found to be 0.76, 0.7, 0.6, and 45 respectively. Further, a 2-2-1 ANN model revealed a good model fit indicating potential utility of the model in the design of nanoparticulate DDS. This present model based on CAMM study could provide a screening interface in the amalgamation of Drug Discovery with possible drug delivery strategies in the discovery stage by permitting evaluation with small drug quantities and minimum experimental runs.
No Reference information available - sign in for access.
No Citation information available - sign in for access.
No Supplementary Data.
No Article Media
No Metrics


Document Type: Research Article

Publication date: December 1, 2005

More about this publication?
  • Journal of Biomedical Nanotechnology (JBN) is a peer-reviewed multidisciplinary journal providing broad coverage in all research areas focused on the applications of nanotechnology in medicine, drug delivery systems, infectious disease, biomedical sciences, biotechnology, and all other related fields of life sciences.
  • Editorial Board
  • Information for Authors
  • Subscribe to this Title
  • Terms & Conditions
  • Ingenta Connect is not responsible for the content or availability of external websites
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more